Lantheus Holdings (LNTH) Stock Price, Quote & News

Company Profile

Lantheus Holdings, Inc. develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in diagnosis and treatment of heart, cancer, and other diseases worldwide. The company offers DEFINITY, an injectable ultrasound enhancing agent used in echocardiography exams; TechneLite, a technetium generator for nuclear medicine procedures; Xenon-133, a radiopharmaceutical gas to assess pulmonary function; Neurolite, an injectable imaging agent to identify the area wi...

Industry: Drug Manufacturers - Specialty & Generic

Sector: Healthcare

Phone: 978 671 8001

Fax: 978 671 8860

Website: www.lantheus.com

Address:

201 Burlington Road, South Building, Bedford, United States

Mrstock23 Jun. 4 at 3:22 PM

$LNTH what are the latest rumors on buyout?

0 · Reply

tomwalt Jun. 4 at 1:55 PM

$LNTH Where are we going

0 · Reply

Trader_Ty Jun. 4 at 1:54 PM

$LNTH 👀

0 · Reply

Merlintrader Jun. 4 at 12:54 PM

$LNTH $SPRO $UNCY June 2026 PDUFA Watchlist: Small and Mid-Cap Biotech Catalysts Beyond Big Pharma https://www.merlintrader.com/june-pdufa-watchlist/

0 · Reply

RadioIsotope25 Jun. 4 at 1:19 AM

$RADX $LNTH $CATX $NNE Radiopharm Theranostics 11.8 million float Nasdaq: RADX Clinical data due in June for RAD-101 https://youtu.be/0GMxcwpyIic

0 · Reply

Lalalilala Jun. 3 at 7:27 PM

$LNTH Things are going well...shouldn't they increase their RADX position from 15% to 100%? 🤣🤣 I'm loaded beyond reason...If the few investors here would like to share their trading views once the RAD101 results are released...🤔

0 · Reply

CapitalMonk Jun. 3 at 5:53 PM

$LNTH Price: $99.72 (+3.55%) Trend: Bullish Market Bias (7D): Bearish Bias 📉 Expected Range: ±0.88% RSI: 55.7 | Momentum: Moderate Volume: -66.7% vs avg Volatility: 2.94% Support: $85.26 | Resistance: $103.89 Data and analytics sourced from Given Analytics educational research: https://www.givenanalytics.com/

0 · Reply

AXLFI_HQ Jun. 3 at 2:54 PM

$LNTH Specialty pharmaceutical and biotech companies are pursuing strategic acquisitions, portfolio optimization, and regulatory approvals to unlock shareholder value and consolidate market position amid capital efficiency pressures. Learn more: https://axlfi.com/themes/309

0 · Reply

Trader_Ty Jun. 2 at 6:20 PM

$LNTH come to tyty

0 · Reply

RadioIsotope25 Jun. 1 at 2:59 PM

$RADX Deal looks off between Curium and $LNTH stock getting hit. Makes more sense for them to acquire rest of RADX to acquire the late stage rad101 potential $500-1billion asset and they own 15% already. Could expand market cap $2.5 billion

0 · Reply

Lantheus Holdings Transcript: 46th Annual William Blair Growth Stock Conference

Jun 3, 2026, 8:30 AM EDT - 1 day ago

Lantheus to Present at the Goldman Sachs 47th Annual Global Healthcare Conference

Jun 2, 2026, 8:00 AM EDT - 2 days ago

Lantheus' LNTH-2513 (18F-GP1) PET/CT Awarded SNMMI's Image of the Year

2026-05-27T12:52:54.000Z - 8 days ago

Lantheus price target raised to $115 from $100 at Mizuho

May 27, 2026, 8:30 AM EDT - 8 days ago

Lantheus to Present at the William Blair 46th Annual Growth Stock Conference

May 22, 2026, 4:27 PM EDT - 13 days ago

Lantheus weighs potential $7 billion sale, Bloomberg News reports

2026-05-22T20:01:33.000Z - 13 days ago

Lantheus weighs sale after Curium takeover offer, Bloomberg says

2026-05-22T20:00:48.000Z - 13 days ago

Lantheus jumps after Bloomberg says company weighing possible sale

May 21, 2026, 8:30 AM EDT - 14 days ago

Lantheus Highlights New Radiodiagnostic Data at the 2026 SNMMI Annual Meeting

May 19, 2026, 8:30 AM EDT - 16 days ago

Lantheus Announces Presentation of Data at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting

2026-05-11T19:44:38.000Z - 24 days ago

Lantheus price target raised to $115 from $98 at Truist

2026-05-08T13:19:29.000Z - 27 days ago

Lantheus price target raised to $100 from $95 at Mizuho

2026-05-08T10:00:53.000Z - 27 days ago

Lantheus price target raised to $115 from $85 at Citizens

2026-05-07T23:08:10.000Z - 27 days ago

Lantheus price target raised to $94 from $82 at Goldman Sachs

May 7, 2026, 8:00 AM EDT - 4 weeks ago

Lantheus Holdings Earnings Call Transcript: Q1 2026

May 7, 2026, 8:00 AM EDT - 4 weeks ago

Lantheus Holdings Earnings release: Q1 2026

May 7, 2026, 8:00 AM EDT - 4 weeks ago

Lantheus Holdings Slides: Q1 2026

May 7, 2026, 8:00 AM EDT - 4 weeks ago

Lantheus Holdings Quarterly report: Q1 2026

May 7, 2026, 7:00 AM EDT - 4 weeks ago

Lantheus Reports First Quarter 2026 Financial Results and Provides Business Update

2026-05-01T13:49:23.000Z - 4 weeks ago

Lantheus price target raised to $97 from $84 at B. Riley

2026-04-15T12:38:30.000Z - 7 weeks ago

Lantheus price target raised to $98 from $89 at Truist

2026-04-13T14:46:36.000Z - 7 weeks ago

Lantheus price target raised to $95 from $85 at Mizuho

Mar 20, 2026, 8:00 AM EDT - 2 months ago

Lantheus Holdings Proxy statement: Proxy filing

Mar 20, 2026, 8:00 AM EDT - 2 months ago

Lantheus Holdings Proxy statement: Proxy filing

2026-03-17T20:22:00.000Z - 2 months ago

Lantheus announces three-month extension of LNTH-2501 PDUFA date

Mar 17, 2026, 4:01 PM EDT - 2 months ago

Lantheus Announces Three-Month Extension of PDUFA Date for LNTH-2501 (Ga 68 edotreotide), a PET Diagnostic Imaging Kit Targeting Somatostatin Receptor-Positive (SSTR+) Neuroendocrine Tumors (NETs)

2026-03-17T19:25:19.000Z - 2 months ago

Lantheus price target raised to $110 from $105 at Jefferies

Mar 10, 2026, 8:00 AM EDT - 3 months ago

Lantheus Holdings Transcript: Leerink Global Healthcare Conference 2026

Mar 10, 2026, 8:00 AM EDT - 3 months ago

Lantheus Holdings Proxy statement: Proxy filing

2026-03-06T21:05:15.000Z - 3 months ago

Lantheus announces FDA approval of Pylarify TruVu injection

Mar 6, 2026, 4:01 PM EST - 3 months ago

Lantheus Announces FDA Approval of PYLARIFY TruVu™ (piflufolastat F 18) Injection

Mar 3, 2026, 11:10 AM EST - 3 months ago

Lantheus Holdings Transcript: TD Cowen 46th Annual Health Care Conference

Mar 2, 2026, 12:19 PM EST - 3 months ago

Lantheus Holdings Investigation Initiated: Kahn Swick & Foti, LLC Investigates the Officers and Directors of Lantheus Holdings, Inc. - LNTH

2026-03-02T13:51:41.000Z - 3 months ago

Lantheus receives U.S. FDA tentative approval for Lutetium Lu 177

2026-03-02T12:33:17.000Z - 3 months ago

Lantheus price target raised to $89 from $82 at Truist

2026-03-02T12:29:38.000Z - 3 months ago

Lantheus price target raised to $89 from $82 at Truist

2026-02-27T12:48:01.000Z - 3 months ago

Lantheus price target raised to $85 from $72 at Mizuho

2026-02-27T10:55:33.000Z - 3 months ago

Lantheus price target raised to $85 from $78 at Citizens

Feb 26, 2026, 8:00 AM EST - 3 months ago

Lantheus Holdings Earnings Call Transcript: Q4 2025

Feb 26, 2026, 8:00 AM EST - 3 months ago

Lantheus Holdings Annual report: Q4 2025

Feb 26, 2026, 8:00 AM EST - 3 months ago

Lantheus Holdings Earnings release: Q4 2025

Feb 26, 2026, 8:00 AM EST - 3 months ago

Lantheus Holdings Slides: Q4 2025

Feb 26, 2026, 7:00 AM EST - 3 months ago

Lantheus Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update

Feb 12, 2026, 8:00 AM EST - 4 months ago

Lantheus to Host Fourth Quarter and Full Year 2025 Earnings Conference Call and Webcast on February 26, 2026, at 8:00 a.m. Eastern Time

Jan 2, 2026, 8:00 AM EST - 5 months ago

Lantheus Announces Closing of SPECT Business Sale to SHINE Technologies

Dec 7, 2025, 11:21 AM EST - 6 months ago

Grabar Law Office Investigates Claims on Behalf of Long-Term Shareholders of Lantheus Holdings, Inc. (LNTH)

Nov 6, 2025, 8:00 AM EST - 7 months ago

Lantheus Holdings Earnings Call Transcript: Q3 2025

Nov 6, 2025, 8:00 AM EST - 7 months ago

Lantheus Holdings Quarterly report: Q3 2025

Nov 6, 2025, 8:00 AM EST - 7 months ago

Lantheus Holdings Earnings release: Q3 2025

Nov 6, 2025, 8:00 AM EST - 7 months ago

Lantheus Holdings Slides: Q3 2025

Nov 6, 2025, 7:02 AM EST - 7 months ago

Lantheus Reports Third Quarter 2025 Financial Results and Provides Business Update

Oct 27, 2025, 10:08 AM EDT - 7 months ago

LANTHEUS HOLDINGS, INC. (NASDAQ: LNTH) DEADLINE ALERT Bernstein Liebhard LLP Reminds Lantheus Holdings, Inc. Investors of Upcoming Deadline

Oct 23, 2025, 8:30 AM EDT - 8 months ago

Lantheus to Host Third Quarter 2025 Earnings Conference Call and Webcast on November 6, 2025, at 8:00 a.m. Eastern Time

Sep 24, 2025, 1:00 AM EDT - 9 months ago

Lantheus and GE HealthCare Announce Exclusive Licensing Agreement for Prostate Cancer Imaging Agent PYLARIFY® (Piflufolastat F 18) in Japan

Sep 22, 2025, 5:29 AM EDT - 9 months ago

Lantheus Holdings, Inc. Investigated for Securities Fraud Violations - Contact the DJS Law Group to Discuss Your Rights - LNTH

Sep 19, 2025, 6:33 PM EDT - 9 months ago

Did you lose money in LNTH? Shareholders Who Incurred Significant Losses in Lantheus Holdings, Inc. Should Contact Robbins LLP for Information

Sep 10, 2025, 8:00 PM EDT - 9 months ago

Gainey McKenna & Egleston Announces A Class Action Lawsuit Has Been Filed Against Lantheus Holdings, Inc. (LNTH)

Mrstock23 Jun. 4 at 3:22 PM

$LNTH what are the latest rumors on buyout?

0 · Reply

tomwalt Jun. 4 at 1:55 PM

$LNTH Where are we going

0 · Reply

Trader_Ty Jun. 4 at 1:54 PM

$LNTH 👀

0 · Reply

Merlintrader Jun. 4 at 12:54 PM

$LNTH $SPRO $UNCY June 2026 PDUFA Watchlist: Small and Mid-Cap Biotech Catalysts Beyond Big Pharma https://www.merlintrader.com/june-pdufa-watchlist/

0 · Reply

RadioIsotope25 Jun. 4 at 1:19 AM

$RADX $LNTH $CATX $NNE Radiopharm Theranostics 11.8 million float Nasdaq: RADX Clinical data due in June for RAD-101 https://youtu.be/0GMxcwpyIic

0 · Reply

Lalalilala Jun. 3 at 7:27 PM

0 · Reply

CapitalMonk Jun. 3 at 5:53 PM

0 · Reply

AXLFI_HQ Jun. 3 at 2:54 PM

0 · Reply

Trader_Ty Jun. 2 at 6:20 PM

$LNTH come to tyty

0 · Reply

RadioIsotope25 Jun. 1 at 2:59 PM

0 · Reply

GwadaLuvM0n3y May. 31 at 9:26 AM

$LNTH I feel like its going to pop tomorrow

0 · Reply

RadioIsotope25 May. 29 at 2:18 PM

$LNTH $RADX https://simplywall.st/stocks/us/healthcare/nasdaq-lnth/lantheus-holdings/news/lantheus-asco-data-to-test-radiopharma-pipeline-and-valuatio/amp

0 · Reply

Trader_Ty May. 28 at 4:29 PM

$LNTH this got all time high look. Get me closer to the weekly 9ema for a possible trade

0 · Reply

tomwalt May. 28 at 3:55 PM

$LNTH Got a feeling that news is coming

0 · Reply

RadioIsotope25 May. 27 at 2:09 PM

$LNTH Deal makes little sense @ $7 bil

0 · Reply

RadioIsotope25 May. 26 at 4:31 PM

$LNTH They can increase revenue by $500 million by acquiring rad101 from $RADX better off going it alone.

0 · Reply

RadioIsotope25 May. 26 at 1:37 PM

New wave of radiopharmaceutical buyouts has begun. If rad101 does peak $500 million USA and $500 million globally in brain imaging that’s a $5 billion market cap asset after reaching peak sales per Curium:Lantheus buyout multiple. 24 mos to fda approval. 90% concordance with mri and 300,000 us patient population ceo comes form Novartis $RADX $LNTH $NVS $AKTS

0 · Reply

RadioIsotope25 May. 26 at 2:14 AM

Abstract CT046: A first-in-class HER2-targeted radiopharmaceutical therapy: Initial findings from the Phase 0/1 HEAT trial of 177Lu-RAD202 in HER2+ advanced solid tumors | Cancer Research | American Association for Cancer Research $RADX $IMNM $AKTS $LNTH https://aacrjournals.org/cancerres/article/86/8_Supplement/CT046/783138

0 · Reply

Mrstock23 May. 26 at 12:11 AM

$LNTH hopefully we go up even more at open tomorrow. Who's going to hold and who's going to sell? I feel like not a lot of upside anymore unless there's another bid so thinking of selling

1 · Reply

CharlieeMungerTWITS May. 25 at 5:40 PM

$LNTH

0 · Reply

RadioIsotope25 May. 24 at 6:31 PM

$RADX $LNTH $AKTS https://chatgpt.com/s/m_6a1343d7a6fc8191881593e2a8b87370

1 · Reply

Lalalilala May. 24 at 4:26 PM

$LNTH So who's going to pay? 🟩 Option 1 — An industrial partner (most likely) This is the standard model in radiopharmaceuticals. Companies capable of paying for a Phase 3 trial: - Curium - Lantheus - Telix - GE Healthcare - Siemens Healthineers - Bracco These groups have: - manufacturing facilities - distribution networks - clinical teams - budgets ($200–500 million per year in R&D) 👉 They finance Phase 3 in exchange for: - commercial rights - revenue sharing - or a complete acquisition

0 · Reply

Market Cap	6.27B
Revenue (ttm)	1.54B
Net Income (ttm)	233.56M
EPS (ttm)	N/A
PE Ratio	19.50
Forward PE	22.03
Profit Margin	15.15%
Debt to Equity Ratio	0.47

Volume	826,240
Avg Vol	938,430
Day's Range	N/A - N/A
Shares Out	65.11M
Stochastic %K	35%
Beta	-0.03
Analysts	Strong Sell
Price Target	$104.75